Taken together, these results suggest that DKK1 contributes to fibroblast activation and cancer cell-fibroblast interaction in high DKK1-expressing tumors, highlightning DKK1 as a potential therapeutic target across various cancer types, not just in gefitinib-resistant NSCLC. Here, DKK1 is linked to cancer.